[Corrections] Correction to Lancet Oncol 2017; 18: 917–28

Stebbing J, Baranau Y, Baryash V, et al. CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial. Lancet Oncol 2017; 18: 917–28—Justin Stebbing's affiliations should have read "Division of Cancer, Department of Surgery and Cancer, Imperial College London, London, UK", and his Declaration of Interests statement should have read "JS is supported by the Biomedical Research Centre, Imperial College London, and the National Institute for Health Research." This correction has been made to the online version as of July 26, 2017.

http://ift.tt/2tEpO8x